NCT02138955View on ClinicalTrials.gov

A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

November 30, 2017

Study Completion Date

February 15, 2018

Conditions
Patients w/Advanced Cancer That Failed Std of Care Therapy
Interventions
DRUG

Liposomeal curcumin

Trial Locations (2)

5020

3 Medicizinische Universitatsklinik Hematologie,Internistische Onkologie, Salzburg

3. Medizinische Universitatesclinik, Haematologie, Internistische Onkologie, Salzburg

All Listed Sponsors
lead

SignPath Pharma, Inc.

INDUSTRY

NCT02138955 - A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer | Biotech Hunter | Biotech Hunter